State Key Laboratory of Targeting Oncology, National Center for International Research of Biotargeting Theranostics, Guangxi Key Laboratory of Biotargeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China.
School of Pharmacy, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Clin Transl Oncol. 2024 Apr;26(4):797-807. doi: 10.1007/s12094-023-03304-4. Epub 2023 Sep 23.
Tumor cells must resist the host's immune system while maintaining growth under harsh conditions of acidity and hypoxia, which indicates that tumors are more robust than normal tissue. Immunotherapeutic agents have little effect on solid tumors, mostly because of the tumor density and the difficulty of penetrating deeply into the tissue to achieve the theoretical therapeutic effect. Various therapeutic strategies targeting the tumor microenvironment (TME) have been developed. Immunometabolic disorders play a dominant role in treatment resistance at both the TME and host levels. Understanding immunometabolic factors and their treatment potential may be a way forward for tumor immunotherapy. Here, we summarize the metabolism of substances that affect tumor progression, the crosstalk between the TME and immunosuppression, and some potential tumor-site targets. We also summarize the progress and challenges of tumor immunotherapy.
肿瘤细胞在酸性和缺氧等恶劣条件下生长时必须抵抗宿主的免疫系统，这表明肿瘤比正常组织更具韧性。免疫治疗药物对实体瘤的作用不大，主要是因为肿瘤密度大，难以深入组织以达到理论治疗效果。已经开发了各种针对肿瘤微环境 (TME) 的治疗策略。在 TME 和宿主水平上，免疫代谢紊乱在治疗抵抗中起主导作用。了解免疫代谢因素及其治疗潜力可能是肿瘤免疫治疗的一个方向。在这里，我们总结了影响肿瘤进展的物质代谢、TME 与免疫抑制之间的相互作用以及一些潜在的肿瘤部位靶点。我们还总结了肿瘤免疫治疗的进展和挑战。
